Boston Scientific (NYSE:BSX) Stock Price Target Raised at Robert W. Baird

Boston Scientific (NYSE:BSX) had its price objective upped by stock analysts at Robert W. Baird from $50.00 to $51.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird‘s price objective would suggest a potential upside of 21.16% from the company’s previous close.

Other analysts have also issued reports about the company. Raymond James Financial reiterated an “outperform” rating and set a $57.00 price target (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Royal Bank Of Canada decreased their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $60.00 target price (down from $75.00) on shares of Boston Scientific in a research note on Thursday, July 30th. Weiss Ratings restated a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Finally, BTIG Research reduced their price target on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating for the company in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $63.77.

Boston Scientific Trading Down 6.6%

Shares of Boston Scientific stock opened at $42.09 on Thursday. The stock has a fifty day simple moving average of $45.12 and a 200 day simple moving average of $57.43. Boston Scientific has a 12-month low of $39.57 and a 12-month high of $105.65. The company has a market capitalization of $61.00 billion, a P/E ratio of 17.04, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.07 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.75 EPS. On average, sell-side analysts anticipate that Boston Scientific will post 3.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Edward Ludwig acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director David Habiger bought 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Boston Scientific during the third quarter valued at about $17,463,000. Vise Technologies Inc. lifted its stake in shares of Boston Scientific by 22.6% in the 3rd quarter. Vise Technologies Inc. now owns 35,744 shares of the medical equipment provider’s stock valued at $1,560,000 after acquiring an additional 6,585 shares during the last quarter. Cidel Asset Management Inc. purchased a new stake in Boston Scientific during the 3rd quarter valued at about $212,000. MGO One Seven LLC grew its position in Boston Scientific by 1.9% during the 3rd quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock worth $614,000 after acquiring an additional 260 shares during the last quarter. Finally, Americana Partners LLC purchased a new position in Boston Scientific in the 3rd quarter worth approximately $740,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue rose 1.5% to $5.138 billion, exceeding analysts’ $5.07 billion estimate, while adjusted EPS of $0.73 matched expectations. Management also reaffirmed its long-term growth strategy and highlighted progress in clinical programs and FDA clearances. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management expects approximately 4% organic revenue growth for full-year 2026 and is targeting a recovery cycle after anticipated 2027 weakness, followed by expansion toward 2030. Recent insider activity also showed purchases rather than sales, including a substantial purchase by CEO Michael Mahoney. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Needham lowered its price target from $57 to $48 but maintained a Buy rating, while JPMorgan downgraded BSX from Overweight to Neutral and set a $46 target. The revised targets remain above the stock’s recent trading level but reflect reduced confidence in the near-term outlook.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to disrupt operations, customer activity, and the recovery timeline. Boston Scientific cut its full-year EPS outlook to $3.16–$3.18 and expects fourth-quarter reported and organic sales to decline 1%–3%. Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide
• Negative Sentiment: Investors are also concerned about contracting margins, weaker heart-device demand, pricing pressure in China, and management’s warning that 2027 could be difficult. GAAP EPS fell to $0.40 from $0.51 a year earlier, and the stock has traded near a four-year low.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.